Summary
The detection of minimal amounts of melanoma cells by tyrosinase reverse transcription polymerase chain reaction (RT-PCR) is seriously hampered by false negative reports in blood of melanoma patients with disseminated melanoma. Therefore, additional assays which make use of multiple melanoma markers are needed. It has been shown that introduction of multiple markers increases the sensitivity of detection. Melanoma inhibitory activity (MIA) is one such melanoma-specific candidate gene. To test the specificity of MIA PCR, we performed 30 and 60 cycles of PCR with two different sets of MIA specific primers on 19 melanoma and 16 non-melanoma cell lines. MIA mRNA was detected in 16 out of 19 melanoma cell lines and in seven out of 16 non-melanoma cell lines after 30 cycles of PCR. However, MIA mRNA could be detected in all cell lines after 60 cycles of PCR. Also, in 14 out of 14 blood samples of melanoma patients, five out of six blood samples of non-melanoma patients and in seven out of seven blood samples of healthy volunteers, MIA mRNA was detected after 60 cycles of PCR, whereas no MIA PCR product could be detected in any of the blood samples after 30 cycles of PCR. We conclude that low levels of MIA transcripts are present in various normal and neoplastic cell types. Therefore, MIA is not a suitable marker gene to facilitate the detection of minimal amounts of melanoma cells in blood or in target organs of the metastatic process.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Blesch, A, Bosserhoff, A-K, Apfel, R, Behl, C, Hessdoerfer, B, Schmitt, A, Jachimczak, P, Lottspeich, F, Buettner, R & Bogdahn, U (1994). Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res 54: 5695–5701.
Bosserhoff, A-K, Hein, R, Bogdahn, U & Buettner, R (1996). Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA. J Biol Chem 271: 490–495.
Bosserhoff, A-K, Kaufmann, M, Kaluza, B, Bartke, I, Zirngibl, H, Hein, R, Stolz, W & Buettner, R (1997). Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57: 3149–3153.
Brossart, P, Keilholz, U, Willhauck, M, Scheibenbogen, C, Mohler, T & Hunstein, W (1993). Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol 101: 887–889.
Brossart, P, Schmier, J-W, Kruger, S, Willhauck, M, Scheibenbogen, C, Mohler, T & Keilholz, U (1995). A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res 55: 4065–4068.
Brouwenstijn, N, Slager, EH, Bakker, ABH, Schreurs, MWJ, Van der Spek, CW, Adema, GJ, Schrier, PI & Figdor, CG (1997). Transcription of the gene encoding melanoma-associated antigen gp100 in tissues and cell lines other than those of the melanocytic lineage. Br J Cancer 76: 1562–1566.
Burchill, SA, Bradbury, FM, Pittman, K, Southgate, J, Smith, B & Selby, P (1995). Detection of epithelial cancer cells in peripheral blood by reverse transcription-polymerase chain reaction. Br J Cancer 71: 278–281.
Chelly, J, Concordet, J, Kaplan, J & Kahn, A (1989). Illegitimate transcription: transcription of any gene in any cell type. Proc Natl Acad Sci USA 86: 2617–2621.
Curry, BJ, Myers, K & Hersey, P (1998). Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. J Clin Oncol 16: 1760–1769.
De Vries, TJ, Fourkour, A, Wobbes, T, Verkroost, G, Ruiter, DJ & Van Muijen, GNP (1997). Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1 and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res 57: 3223–3229.
De Vries, TJ, Fourkour, A, Punt, CJA, Van de Locht, LT, Wobbes, T, Van den Bosch, S, De Rooij, MJM, Mensink, EJ, Ruiter, DJ & Van Muijen, GNP (1999). Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative PCR. Br J Cancer 80: 883–891.
Hoon, DS, Wang, Y, Dale, PS, Conrad, AJ, Schmid, P, Garrison, D, Kuo, C, Foshag, LJ, Nizze, AJ & Morton, DL (1995). Detection of occult melanoma cells in the blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 13: 2109–2116.
Keilholz, U (1996). Diagnostic PCR in melanoma: methods and quality assurance. Eur J Cancer 32: 1661–1663.
Keiholz, U, Willhauck, M, Scheibenbogen, C, De Vries, TJ & Burchill, S (1997). Polymerase chain reaction detection of circulating tumour cells. Melanoma Res 7: S133–S141.
Kunter, U, Buer, J, Probst, M, Duensing, S, Dallmann, I, Grosse, J, Kirchner, H, Schluepen, EM, Volkenandt, M, Ganser, A & Atzpodien, J (1996). Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst 88: 590–594.
La Valle, GJ, Williams, NY, Walker, MJ, Triozzi, PL & Barbera-Guillem, E (1998). Expression of melanoma inhibitory activity in the peripheral blood of melanoma patients by the reverse transcription-polymerase chain reaction (RT-PCR). Proc Am Assoc Cancer Res 39: 229(Abstract).
Mellado, B, Colomer, D, Castel, T, Munoz, M, Carballo, E, Galan, M, Mascaro, JM, Vives-Corrons, JL, Grau, JJ & Estape, J (1996). Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J Clin Oncol 14: 2091–2097.
Mori, M, Mimori, K, Tanaka, F, Ueo, H, Sugimachi, K & Akiyoshi, T (1997). Molecular diagnosis of circulating cancer cells using MAGE gene assays. JAMA 278: 476–477.
Smith, B, Selby, P, Southgate, J, Pittman, K, Bradley, C & Blair, GE (1991). Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338: 1227–1229.
Van Groningen, JJM, Bloemers, HPJ & Swart, GWM (1995). Identification of melanoma inhibitory activity and other differentially expressed messenger RNAs in human melanoma cell lines with different metastatic capacity by messenger RNA differential display. Cancer Res 55: 6237–6243.
Wimmer, M, Meyer, JC, Seifert, B, Dummer, R, Flace, A & Burg, G (1997). Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Cancer Res 57: 5073–5076.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Vries, T., Fourkour, A., Punt, C. et al. Melanoma-inhibiting activity (MIA) mRNA is not exclusively transcribed in melanoma cells: low levels of MIA mRNA are present in various cell types and in peripheral blood. Br J Cancer 81, 1066–1070 (1999). https://doi.org/10.1038/sj.bjc.6690808
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690808